Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 08:45 ET | Source: Clene Inc.

Clene Announces $7 Million Underwritten Offering of Common Stock

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late...
May 05, 2026 08:00 ET | Source: Clene Inc.

Clene to Present at Upcoming May Conferences

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Trasplante de órganos: ALS obtiene el marcado CE para PERLA®, una nueva clase de solución – PPS – desarrollada junto al IDIBAPS (Barcelona), y lanza un estudio clínico comparativo

comunicado de prensa Trasplante de órganos: ALS obtiene el marcado CE para PERLA®, una nueva clase de solución – PPS – desarrollada junto al IDIBAPS (Barcelona), y lanza un estudio clínico...
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative

COMMUNIQUÉ DE PRESSE Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative Obtention du marquage CE...
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT)

Press Release Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT) ALS has received CE...
May 04, 2026 08:00 ET | Source: Clene Inc.

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker...
April 28, 2026 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Marks ALS Awareness Month throughout May with Breakthrough Research, Powerful Stories, and Nationwide Call to Action to End ALS

New York, April 28, 2026 (GLOBE NEWSWIRE) -- During ALS Awareness Month this May, the Muscular Dystrophy Association (MDA) is highlighting unprecedented scientific progress, inspiring personal...
April 21, 2026 10:42 ET | Source: Trethera Corporation

Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors

Drew Woodmansee Board Appointment strengthens Trethera with deep patent expertise and capital formation experience, supporting its next phase of growth.
April 20, 2026 15:32 ET | Source: AB Science

AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV DÉMONTRANT DES BÉNÉFICES SUBSTANTIELS EN TERMES DE SURVIE ET DE QUALITÉ DE VIE PRÉSERVÉE AVEC LE MASITINIB CHEZ LES...
April 20, 2026 15:32 ET | Source: AB Science

AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS ...